Pallauf, M., Rezaee, M., Elias, R., Wlajnitz, T., Fletcher, S. A., Cheaib, J., Alkhatib, K., Chang, P., Wagner, A. A., McKiernan, J. M., Allaf, M. E., Pierorazio, P. M., & Singla, N. (2025). Tumour size is associated with growth rates of >0.5 cm/year and delayed intervention in small renal masses in patients on active surveillance. BJU International. Portico. https://doi.org/10.1111/bju.16651

Sommerhalder, D., Demel, K., Noel, M. S., Emamekhoo, H., Peguero, J., Balaraman, R., Moy, R. H., Scheuber, A., Haas, J., Chabas, D., Kumar, P., Daigle, S. R., Dasen, S., Zhang, X., Gutierrez, M., Sharma, S., & Hussain, A. (2024). 682 Ongoing phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: clinical safety update and renal cell carcinoma (RCC) efficacy analysis. Regular and Young Investigator Award Abstracts, A782–A783. https://doi.org/10.1136/jitc-2024-sitc2024.0682

Frank, J. S., Thomas, A. S., & Kluger, M. D. (2024). The role of CT imaging in proposed algorithm for managing post-operative hemorrhage after pancreaticoduodenectomy: case series. Surgery Case Reports, 3, 100042. https://doi.org/10.1016/j.sycrs.2024.100042

Atkins, M. B., Jegede, O. A., Haas, N. B., Mcdermott, D. F., Bilen, M. A., Stein, M., Sosman, J., Alter, R., Plimack, E. R., Ornstein, M. C., Hurwitz, M., Peace, D. J., Einstein, D., Catalano, P. J., Hammers, H., & Regan, M. M. (2024). Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for ImmunoTherapy of Cancer, 12(4), e008293. https://doi.org/10.1136/jitc-2023-008293

Ben-Ami, R., Wang, Q.-L., Zhang, J., Supplee, J. G., Fahrmann, J. F., Lehmann-Werman, R., Brais, L. K., Nowak, J., Yuan, C., Loftus, M., Babic, A., Irajizad, E., Davidi, T., Zick, A., Hubert, A., Neiman, D., Piyanzin, S., Gal-Rosenberg, O., Horn, A., … Wolpin, B. M. (2023). Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut, gutjnl-2023-331074. https://doi.org/10.1136/gutjnl-2023-331074

Lee, A., Runcie, K. D., & Yu, J. B. (2024). The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma. Kidney Cancer, 8(1), 45–50. https://doi.org/10.3233/kca-230020

Alam, R., Yerrapragada, A., Wlajnitz, T., Watts, E., Pallauf, M., Enikeev, D., Chang, P., Wagner, A. A., McKiernan, J. M., Pierorazio, P. M., Allaf, M. E., & Singla, N. (2023). Evaluation of Growth Rates for Small Renal Masses in Elderly Patients Undergoing Active Surveillance. European Urology Open Science, 50, 78–84. https://doi.org/10.1016/j.euros.2023.02.004

Yeh, C., Zhou, M., Sigel, K., Jameson, G., White, R., Safyan, R., Saenger, Y., Hecht, E., Chabot, J., Schreibman, S., Juzyna, B., Ychou, M., Conroy, T., Fojo, T., Manji, G. A., Von Hoff, D., & Bates, S. E. (2022). Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. The Oncologist, 28(2), 139–148. https://doi.org/10.1093/oncolo/oyac217

Joshi, M., Tuanquin, L., Zhu, J., Walter, V., Schell, T., Kaag, M., Kilari, D., Liao, J., Holder, S. L., Emamekhoo, H., Sankin, A., Merrill, S., Zheng, H., Warrick, J., Hauke, R., Gartrel, B., Stein, M., Drabick, J., Degraff, D. J., & Zakharia, Y. (2023). Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. Journal for ImmunoTherapy of Cancer, 11(2), e006551. https://doi.org/10.1136/jitc-2022-006551

Alkhafaji, H., & Ibrahim, A. (2022). Effects of Contrast Enhancement Phase on the Reproducibility and Predictivity of CT-Based Renal Lesions Radiomic Features. Applied Sciences, 12(24), 12599. https://doi.org/10.3390/app122412599

Hou, J., Goodman, O., Berz, D., Yao, L., & Soni, N. (2022). 733 A phase 2 study of vudalimab (XmAb®20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer. Regular and Young Investigator Award Abstracts, A765–A765. https://doi.org/10.1136/jitc-2022-sitc2022.0733

Jorgensen, K., Wu, C.-F., Meernik, C., Nitecki, R., Melamed, A., & Rauh-Hain, J. A. (2022). 2022-RA-838-ESGO All-cause and cancer-specific mortality after fertility-sparing surgery for stage I epithelial ovarian cancer. Fertility/Pregnancy, A175.2-A176. https://doi.org/10.1136/ijgc-2022-esgo.375

Ibrahim, A., Lu, L., Yang, H., Akin, O., Schwartz, L. H., & Zhao, B. (2022). The Impact of Image Acquisition Parameters and ComBat Harmonization on the Predictive Performance of Radiomics: A Renal Cell Carcinoma Model. Applied Sciences, 12(19), 9824. https://doi.org/10.3390/app12199824

Bauer, T., Cho, B. C., Heist, R., Bazhenova, L., Werner, T., Goel, S., Kim, D.-W., Adkins, D., Carvajal, R. D., Alva, A., Eaton, K., Wang, J., Liu, Y., Yan, X., Christensen, J., Neuteboom, S., Chao, R., & Pant, S. (2022). First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Investigational New Drugs, 40(5), 990–1000. https://doi.org/10.1007/s10637-022-01274-y

Ingram, M. A., Lauren, B. N., Pumpalova, Y., Park, J., Lim, F., Bates, S. E., Kastrinos, F., Manji, G. A., Kong, C. Y., & Hur, C. (2022). Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports, 5(9). Portico. https://doi.org/10.1002/cnr2.1565

Tourigny, D. S., Zucker, M., Kim, M., Russo, P., Coleman, J., Lee, C.-H., Carlo, M. I., Chen, Y.-B., Hakimi, A. A., Kotecha, R. R., & Reznik, E. (2022). Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.910147